# US 5,352,810 A · Phosphatidylinositol analogues, inhibitors of phosphatidylinositol specific phospholipase C

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,352,810 A
- Document ID: US5352810A
- Status: Granted
- Kind: A
- Application number: 07/824,318
- Filed: 1992-01-23
- Granted: 1994-10-04
- Earliest claimed: 1991-02-01
- Assignees: Mediolanum Farmaceutici S.p.A.
- Inventors: Mario Brufani; Maria Candida Cesta; Enrico Ferrari; Luigi Filocamo; Sperandina Lappa; Stefano Maiorana; Pier Giuseppe Pagella
- Web page: https://patentgrep.com/patent/US5352810A

## CPC

- C07F 9/177: with cycloaliphatic alcohols
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07F 9/117: with cycloaliphatic alcohols
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Phosphatidylinositol analogues, inhibitors of phosphatidylinositol-specific phospholipase C of general formula (I) ##STR1## wherein X and R have the meanings specified in the description, suitable for preparing pharmaceutical compositions for the treatment of tumoral, thrombotic and inflammatory type pathologies.

## Claims

### Claim 1

Phosphatidylinositol analogues, inhibitors of phosphatidylinositol-specific phospholipase C, having the general formula (I) ##STR20## wherein X is S or O, and R has one of the following meanings: 1) a branched or linear alkyl radical selected from the group consisting of octyl, tetradecyl, hexadecyl, octadecyl, and eicosyl;
2) an arylalkyl radical selected from the group consisting of benzyl, phenylethyl, naphthylethyl, phenylpropyl, and phenylhexyl;
3) 2,3 diacyloxypropyl: ##STR21## wherein R.sub.6 is a saturated or unsaturated acyl radical selected from the group consisting of oleyl, linoleyl, linolenyl, myristoyl, and lauroyl;
4) 2,3 dialkyloxypropyl: ##STR22## wherein R.sub.7 is a saturated or unsaturated alkyl radical selected from the group consisting of stearyl, palmityl, oleyl, myristyl, and cetyl;
5) 2,3 alkylacyloxypropyl ##STR23## wherein R.sub.8 is a saturated or unsaturated alkyl radical selected from the group consisting of stearyl, palmityl, oleyl, myristyl, and cetyl and R.sub.9 is acetyl;
6) an alkyl radical containing a carbonyl group of formula:
R.sub.10 --COZ(CH.sub.2).sub.n --
wherein R.sub.10 has the same meaning as R at item 1, Z=O, NH, and n ranges from 2 to 6;
7) an alkyl radical containing a carbonyl group of formula:
R.sub.10 --YCO(CH.sub.2).sub.m --
wherein R.sub.10 has the same meaning as R at item 5, Y=O, NH, S and m ranges from 1 to 6.

### Claim 2

A process for preparing phosphatidylinositol analogue inhibitors of phosphatidylinositol-specific phospholipase C having the following general formula (I): ##STR24## wherein X is S or O, and R has one of the following meanings: 1) a branched or linear alkyl radical selected from the group consisting of octyl, tetradecyl, hexadecyl, octadecyl, and eicosyl;
2) an arylalkyl radical selected from the group consisting of benzyl, phenylethyl, naphthylethyl, phenylpropyl, and phenylhexyl;
3) 2,3 diacyloxypropyl: ##STR25## wherein R.sub.6 is a saturated or unsaturated acyl radical selected from the group consisting of oleyl, linoleyl, linolenyl, myristoyl, and lauroyl;
4) 2,3 dialkyloxypropyl: ##STR26## wherein R.sub.7 is a saturated or unsaturated alkyl radical selected from the group consisting of stearyl, palmityl, oleyl, myristyl, and cetyl;
5) 2,3 alkylacyloxypropyl ##STR27## wherein R.sub.8 is a saturated or unsaturated alkyl radical selected from the group consisting of stearyl, palmityl, oleyl, myristyl, and cetyl and R.sub.9 is acetyl;
6) an alkyl radical containing a carbonyl group of formula:
R.sub.10 --COZ(CH.sub.2).sub.n --
wherein R.sub.10 has the same meaning as R at item 1, Z=O, NH, and n ranges from 2 to 6;
7) an alkyl radical containing a carbonyl group of formula:
R.sub.10 --YCO(CH.sub.2).sub.m --
wherein R.sub.10 has the same meaning as R at item 5, Y=O, NH, S and m ranges from 1 to 6; wherein when X=S, said process comprises:
(a) transesterifying by treatment with trimethylsilylbromide a diethylphosphothiolate having the general formula: ##STR28## (b) treating the transesterified product of step (a) with myoinositol protected at hydroxyl groups 2, 3, 4, 5 and 6 in the presence of a condensing agent; and
(c) removing the protecting groups of the compound produced in step (b) and thereby restoring the hydroxyl groups 2, 3, 4, 5 and 6;
and wherein when X=O, said process comprises:
(a) transesterifying by treatment with trimethylsilylbromide a phosphoric triester having the formula: ##STR29## (b) treating the transesterified product of step (a) with myoinositol protected at hydroxyl groups 2, 3, 4, 5 and
(c) removing the protecting groups of the compound produced in step (b) and thereby restoring the hydroxyl groups 2, 3, 4, 5 and 6.

### Claim 3 (depends on 2)

The process according to claim 2 wherein said transesterification is carried out in CH.sub.2 Cl.sub.2 under inert gas atmosphere at room temperature and by using a molar ratio of trimethylsilylbromide : phosphothiolate comprised between 2.5 and 4.5.

### Claim 4 (depends on 2)

The process according to claim 2, wherein said myoinositol is protected at said hydroxyl groups with protecting groups selected from benzyl, allyl, trialkylsilyl, alkylarylsilyl, tetrahydropyranyl, acetonitril, cyclohexylidene, acetyl, propanoyl, butirryl, and pentanoyl.

### Claim 5 (depends on 2)

The process according to claim 2, wherein said treatment with myoinositol is carried out in pyridine and triethylamine and optionally CHCl.sub.3 ambient under inert gas atmosphere, at room temperature and by using a molar ratio myoinositol:phosphothiolate comprised between 0.8 and 2.

### Claim 6 (depends on 2)

The process according to claim 2, wherein said remotion of the benzyl protecting groups, in order to restore the hydroxyl groups 2,3,4,5 and 6 is carried out in CHCl.sub.3, under inert gas atmosphere, at room temperature, by using a quantity of from to 25 ml of ethylmercaptan and of from 3 to 5 ml of boron trifluoride etherate per mMol of myo-inositol derivative.